CN1943661B - A Chinese traditional medicinal composition and its preparation method - Google Patents

A Chinese traditional medicinal composition and its preparation method Download PDF

Info

Publication number
CN1943661B
CN1943661B CN2005101078678A CN200510107867A CN1943661B CN 1943661 B CN1943661 B CN 1943661B CN 2005101078678 A CN2005101078678 A CN 2005101078678A CN 200510107867 A CN200510107867 A CN 200510107867A CN 1943661 B CN1943661 B CN 1943661B
Authority
CN
China
Prior art keywords
weight portions
powder
extractum
add
concentrated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2005101078678A
Other languages
Chinese (zh)
Other versions
CN1943661A (en
Inventor
周小明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yangzijiang Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co.,Ltd.
Original Assignee
周小明
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Application filed by 周小明 filed Critical 周小明
Priority to CN2005101078678A priority Critical patent/CN1943661B/en
Publication of CN1943661A publication Critical patent/CN1943661A/en
Application granted granted Critical
Publication of CN1943661B publication Critical patent/CN1943661B/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38043455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1943661(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

This invention provides a Chinese traditional medicinal composition. The medicine is prepared by using the ingredients such like shorthorned epimedium herb, suncured ginseng, hoantchy root, tortoise shell powder, turtle shell powdr, fructus ligustri lucidi, Atractylodes macrocephala, pericarpium citri reticulatae and so on. It is clinically used for treating renal deficiency dui to actinotheraphy, chemotherapy carried for cancerous person. At the same time, it also reveals preparing method.

Description

A kind of Chinese medicine composition and preparation method thereof
Invention field
The present invention relates to the preparation method of a kind of Chinese medicine composition and said composition, particularly a kind ofly be used for the treatment of the syndrome of deficiency of kidney-QI that tumor is put, chemotherapy causes, disease is seen Chinese medicine composition of spiritlessness and weakness, deficiency of QI with disinclination to talk, short breath and preparation method thereof.
Background technology
Malignant tumor is the commonly encountered diseases and the frequently-occurring disease of serious threat human health, and according to World Health Organization's report, in more than 50 hundred million populations of the whole world, the tumor patient of annual new diagnosis is about 9,000,000 people, and dead person reaches 7,000,000 people/a because of tumor, accounts for nearly 20% of total case fatality rate.Drug therapy occupies an important position in three big therapies of malignant tumor, and is with the fastest developing speed.The overwhelming majority is a lead compound with the natural anti-cancer active component in synthetic chemical classes cancer therapy drug, and the exploitation of cancer therapy drug comprises that computer mould fits Bionic Design all based on the natural anti-cancer active component.There is abundant resources of medicinal plant in China, the medical expert of China uses the experience of natural anti-cancer drugs according to various nationalities since the sixties, a collection of determined curative effect, the little natural replenishing QI to invigorate the spleen of untoward reaction from national medicine, have been researched and developed out, kidney tonifying, essence replenishing, the medicine that is used for assistant treating cancer is for due contribution has been made in the control of cancer.
Summary of the invention
One object of the present invention is to provide a kind of replenishing QI to invigorate the spleen that has, and the kidney tonifying, essence replenishing effect, is used for the treatment of the syndrome of deficiency of kidney-QI that tumor is put, chemotherapy causes, disease is seen the Chinese medicine composition of spiritlessness and weakness, deficiency of QI with disinclination to talk, short breath.
The object of the present invention is achieved like this, according to the Chinese medicine and pharmacy theory, utilizes the property of medicine of medical herbs uniqueness, and the crude drug composition and the proportioning of the preparation present composition are as follows:
Herba Epimedii 350~400 weight portions, Radix Ginseng 60~100 weight portions, the Radix Astragali 350~400 weight portions, Testudinis powder 50~80 weight portions, Trionyx sinensis Wiegmann powder 100~150 weight portions, Fructus Ligustri Lucidi 200~250 weight portions, the Rhizoma Atractylodis Macrocephalae 200~250 weight portions, Pericarpium Citri Reticulatae 100~150 weight portions.
The crude drug of the present composition is formed best proportioning:
Herba Epimedii 360 weight portions, Radix Ginseng 80 weight portions, the Radix Astragali 360 weight portions, Testudinis powder 60 weight portions, Trionyx sinensis Wiegmann powder 120 weight portions, Fructus Ligustri Lucidi 240 weight portions, the Rhizoma Atractylodis Macrocephalae 240 weight portions, Pericarpium Citri Reticulatae 120 weight portions.
Clinical use for convenience, the inventor has done further research at this crude drug, to formulate its extraction and preparation technique, is made into various dosage forms clinical or that pharmacy is required, as tablet, capsule, pill, soft capsule etc.The technical study process is as follows:
Get Fructus Ligustri Lucidi powder and be broken into coarse powder, add 10 times of amounts of 70% ethanol, reflux 2 hours filters, and relative density is 1.02~1.06 extractum when reclaiming ethanol and being concentrated into 25 ℃.Other gets the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae extracts volatile oil, and volatile oil beta-schardinger dextrin-inclusion is standby.Medicinal residues and Herba Epimedii, Radix Ginseng, the Radix Astragali are decocted with water secondary, add for the first time 30 times of amounts of water, add for the second time 20 times of amounts of water, the each decoction 2 hours, filter, merging filtrate, filtrate is concentrated into 1/3 of about full dose, centrifugal, relative density was 1.06~1.10 extractum when supernatant continued to be concentrated into 25 ℃.Above-mentioned two kinds of extractum are mixed the spray drying powder that gets dry extract with beta-cyclo dextrin included compound.Dried cream powder and Testudinis powder, Trionyx sinensis Wiegmann powder mixing, promptly.
The present composition is in the syndrome of deficiency of kidney-QI of putting in tumor, chemotherapy causes, disease is seen the application in the medicine of spiritlessness and weakness, deficiency of QI with disinclination to talk, short breath.
Further verify this prescription compositions in vital energy benefiting and the kidney invigorating by in-vitro pharmacological experiments, the effect of immunostimulant aspect:
Laboratory animal health, male, 6 week ages, closed colony KM Mus, body weight 18~22g in 6~8 ages in week, is provided by Beijing's animal center
H22 hepatoma cell strain H22 ascitic type cell strain is available from consonance medical university of Chinese Academy of Medical Sciences institute of materia medica.
The flat Tissue Culture Plate of reagent and instrument RPMI RPMI-1640 and 96 holes (the magnificent biological company limited in Shanghai); FCS (GIBCOBRL company); CO2 constant temperature incubator (MODEL2300SHELDOMANUFACTUERING INC); MTT (the magnificent biological product in Shanghai engineering company), the flat Tissue Culture Plate in 96 holes.
The inoculation and aseptic extraction lotus hepatocarcinoma (H22) the mouse peritoneal hydrops that divides into groups are diluted to PBS and contain oncocyte 1 * 10 7Ml, the right groin subcutaneous vaccination of every Mus 0.1ml is divided into lotus tumor model group, positive control (5-FU) group, present composition group and normal group, 6 every group at random with mice.
Begin administration behind the medication mouse inoculation oncocyte 24h, normal group and lotus tumor model group only gavage cold PBS0.5ml/ every day; Positive controls lumbar injection 5-FU0.2ml/ only, the next day 1 time; Of the present invention group every day lumbar injection 5-FU0.2ml/ only, only irritate stomach medicine 2ml/ of the present invention, 2 times on the one, successive administration 12 days.
12h after the last administration of collection of specimens adopts and plucks eyeball depletion method execution mice, and body weight, the thymic weight of KM Mus respectively organized in weighing, peel off tumor tissues and weigh, and the aseptic spleen of getting weighed.
Monitoring index NK cytoactive is measured: the improvement mtt assay detects.
Statistical procedures SPSS10.0 statistical software carries out date processing, the t check, and P<0.05 is the significance standard.
Table 1 present composition is to the influence of tumor-bearing mice NK cytoactive
Compare with normal group: △ P<0.05
Table 2 present composition is to the influence of tumor-bearing mice body weight, tumor weight, thymic weight and spleen weight
Compare with normal group: △ P<0.05; Compare with lotus tumor model group: P<0.05
The specific embodiment
Illustrate with specific embodiment more below, to the present invention without limits but following embodiment only is used to the present invention is described.
Embodiment 1:
Prescription: the Herba Epimedii 360g Radix Ginseng 80g Radix Astragali (processed with honey) 360g Testudinis powder 60g Trionyx sinensis Wiegmann powder 120g Fructus Ligustri Lucidi (wine steaming) the 240g Rhizoma Atractylodis Macrocephalae (stir-fry) 240g Pericarpium Citri Reticulatae 120g
Method for making: above 8 flavors, get Fructus Ligustri Lucidi powder and be broken into coarse powder, add 10 times of amounts of 70% ethanol, reflux 2 hours filters, and reclaims ethanol and is concentrated into the extractum that relative density is 1.02-1.06 (25 ℃).Other gets the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae extracts volatile oil, and volatile oil beta-schardinger dextrin-inclusion is standby.Medicinal residues and Herba Epimedii, Radix Ginseng, the Radix Astragali are decocted with water secondary, add for the first time 30 times of amounts of water, add for the second time 20 times of amounts of water, the each decoction 2 hours, filter, merging filtrate, filtrate is concentrated into 1/3 of about full dose, centrifugal, supernatant continues to be concentrated into the extractum that relative density is 1.06-1.10 (25 ℃).Above-mentioned two kinds of extractum are mixed the spray drying powder that gets dry extract with beta-cyclo dextrin included compound.Dried cream powder and Testudinis powder, Trionyx sinensis Wiegmann powder mixing, 75% alcohol granulation is pressed into 1000, promptly
Embodiment 2:
Prescription: the Herba Epimedii 360g Radix Ginseng 80g Radix Astragali (processed with honey) 360g Testudinis powder 60g Trionyx sinensis Wiegmann powder 120g Fructus Ligustri Lucidi (wine steaming) the 240g Rhizoma Atractylodis Macrocephalae (stir-fry) 240g Pericarpium Citri Reticulatae 120g
Method for making: above 8 flavors, get Fructus Ligustri Lucidi powder and be broken into coarse powder, add 10 times of amounts of 70% ethanol, reflux 2 hours filters, and reclaims ethanol and is concentrated into the extractum that relative density is 1.02-1.06 (25 ℃).Other gets the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae extracts volatile oil, and volatile oil beta-schardinger dextrin-inclusion is standby.Medicinal residues and Herba Epimedii, Radix Ginseng, the Radix Astragali are decocted with water secondary, add for the first time 30 times of amounts of water, add for the second time 20 times of amounts of water, the each decoction 2 hours, filter, merging filtrate, filtrate is concentrated into 1/3 of about full dose, centrifugal, supernatant continues to be concentrated into the extractum that relative density is 1.06-1.10 (25 ℃).Above-mentioned two kinds of extractum are mixed the spray drying powder that gets dry extract with beta-cyclo dextrin included compound.Dried cream powder and Testudinis powder, Trionyx sinensis Wiegmann powder mixing incapsulate, and make 1000, promptly
Embodiment 3:
Prescription: the Herba Epimedii 720g Radix Ginseng 80g Radix Astragali (processed with honey) 720g Testudinis powder 120g Trionyx sinensis Wiegmann powder 240g Fructus Ligustri Lucidi (wine steaming) the 480g Rhizoma Atractylodis Macrocephalae (stir-fry) 480g Pericarpium Citri Reticulatae 240g
Method for making: above 8 flavors, get Fructus Ligustri Lucidi powder and be broken into coarse powder, add 10 times of amounts of 70% ethanol, reflux 2 hours filters, and reclaims ethanol and is concentrated into the extractum that relative density is 1.02-1.06 (25 ℃).Other gets the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae extracts volatile oil, and volatile oil beta-schardinger dextrin-inclusion is standby.Medicinal residues and Herba Epimedii, Radix Ginseng, the Radix Astragali are decocted with water secondary, add for the first time 30 times of amounts of water, add for the second time 20 times of amounts of water, the each decoction 2 hours, filter, merging filtrate, filtrate is concentrated into 1/3 of about full dose, centrifugal, supernatant continues to be concentrated into the extractum that relative density is 1.06-1.10 (25 ℃).Above-mentioned two kinds of extractum are mixed the spray drying powder that gets dry extract with beta-cyclo dextrin included compound.Dried cream powder and Testudinis powder, Trionyx sinensis Wiegmann powder mixing add carboxymethylstach sodium 40g, microcrystalline Cellulose 100g, and add starch to total amount 1000g, and mix homogeneously is an adhesive system soft material with water, is pressed into ball, drying, and packing, promptly.
Embodiment 4:
Prescription: the Herba Epimedii 360g Radix Ginseng 80g Radix Astragali (processed with honey) 360g Testudinis powder 60g Trionyx sinensis Wiegmann powder 120g Fructus Ligustri Lucidi (wine steaming) the 240g Rhizoma Atractylodis Macrocephalae (stir-fry) 240g Pericarpium Citri Reticulatae 120g
Method for making: above 8 flavors, get Fructus Ligustri Lucidi powder and be broken into coarse powder, add 10 times of amounts of 70% ethanol, reflux 2 hours filters, and reclaims ethanol and is concentrated into the extractum that relative density is 1.02-1.06 (25 ℃).Other gets the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae extracts volatile oil, and volatile oil beta-schardinger dextrin-inclusion is standby.Medicinal residues and Herba Epimedii, Radix Ginseng, the Radix Astragali are decocted with water secondary, add for the first time 30 times of amounts of water, add for the second time 20 times of amounts of water, the each decoction 2 hours, filter, merging filtrate, filtrate is concentrated into 1/3 of about full dose, centrifugal, supernatant continues to be concentrated into the extractum that relative density is 1.06-1.10 (25 ℃).Above-mentioned two kinds of extractum are mixed the spray drying powder that gets dry extract with beta-cyclo dextrin included compound.Dried cream powder and Testudinis powder, Trionyx sinensis Wiegmann powder mixing, (soybean oil is heated to 60~70 ℃, adds 4% Cera Flava, stirs to make and dissolves, and promptly) to total amount 600g, colloid mill ground 5 minutes, suppressed soft capsule, and drying is made 1000 of soft capsules, packs, promptly to add substrate.

Claims (6)

1. oral Chinese medicine compositions with vital energy benefiting and the kidney invigorating, immunological enhancement is characterized in that said composition made by following medicine:
Herba Epimedii 350~400 weight portions, Radix Ginseng 60~100 weight portions, the Radix Astragali 350~400 weight portions, Testudinis powder 50~80 weight portions, Trionyx sinensis Wiegmann powder 100~150 weight portions, Fructus Ligustri Lucidi 200~250 weight portions, the Rhizoma Atractylodis Macrocephalae 200~250 weight portions and Pericarpium Citri Reticulatae 100~150 weight portions.
2. Chinese medicine composition according to claim 1 is characterized in that said composition made by following medicine:
Herba Epimedii 360 weight portions, Radix Ginseng 80 weight portions, the Radix Astragali 360 weight portions, Testudinis powder 60 weight portions, Trionyx sinensis Wiegmann powder 120 weight portions, Fructus Ligustri Lucidi 240 weight portions, the Rhizoma Atractylodis Macrocephalae 240 weight portions and Pericarpium Citri Reticulatae 120 weight portions.
3. Chinese medicine composition according to claim 1 and 2 is characterized in that the dosage form that can make at last is any in tablet, hard capsule, pill and the soft capsule.
4. according to the preparation method of the described Chinese medicine composition of claim 3, it is characterized in that comprising following technical process:
Get Fructus Ligustri Lucidi, add 60~80% alcohol heating reflux 1~3 hour, filter, reclaiming ethanol and being concentrated into relative density is 1.02~1.06 extractum; Other gets the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae extracts volatile oil, and volatile oil beta-schardinger dextrin-inclusion is standby; Medicinal residues and Herba Epimedii, Radix Ginseng, the Radix Astragali are decocted with water 2~3 times, decocted 2~3 hours at every turn, filter, merging filtrate, centrifugal, it is 1.06~1.10 extractum that supernatant continues to be concentrated into relative density; Above-mentioned two kinds of extractum are mixed the spray drying powder that gets dry extract with beta-cyclo dextrin included compound; Dried cream powder and Testudinis powder, Trionyx sinensis Wiegmann powder mixing add conventional adjuvant, make in tablet, hard capsule, pill and the soft capsule any.
5. the preparation method of Chinese medicine composition according to claim 4, its detailed features is:
Get Fructus Ligustri Lucidi powder and be broken into coarse powder, add 10 times of amounts of 70% ethanol, reflux 2 hours filters, and relative density is 1.02~1.06 extractum when reclaiming ethanol and being concentrated into 25 ℃; Other gets the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae extracts volatile oil, and volatile oil beta-schardinger dextrin-inclusion is standby; Medicinal residues and Herba Epimedii, Radix Ginseng, the Radix Astragali are decocted with water secondary, add for the first time 30 times of amounts of water, add for the second time 20 times of amounts of water, the each decoction 2 hours, filter, merging filtrate, filtrate is concentrated into 1/3 of about full dose, centrifugal, relative density was 1.06~1.10 extractum when supernatant continued to be concentrated into 25 ℃; Above-mentioned two kinds of extractum are mixed the spray drying powder that gets dry extract with beta-cyclo dextrin included compound; Dried cream powder and Testudinis powder, Trionyx sinensis Wiegmann powder mixing; Add suitable adjuvant, make in tablet, hard capsule, pill and the soft capsule any.
6. pharmaceutical composition as claimed in claim 1 or 2 is used for the treatment of the syndrome of deficiency of kidney-QI that tumor is put, chemotherapy causes in preparation, and disease is seen the application in the medicine of spiritlessness and weakness, deficiency of QI with disinclination to talk, short breath.
CN2005101078678A 2005-10-08 2005-10-08 A Chinese traditional medicinal composition and its preparation method Active CN1943661B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2005101078678A CN1943661B (en) 2005-10-08 2005-10-08 A Chinese traditional medicinal composition and its preparation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2005101078678A CN1943661B (en) 2005-10-08 2005-10-08 A Chinese traditional medicinal composition and its preparation method

Publications (2)

Publication Number Publication Date
CN1943661A CN1943661A (en) 2007-04-11
CN1943661B true CN1943661B (en) 2010-11-10

Family

ID=38043455

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005101078678A Active CN1943661B (en) 2005-10-08 2005-10-08 A Chinese traditional medicinal composition and its preparation method

Country Status (1)

Country Link
CN (1) CN1943661B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103860656A (en) * 2012-12-11 2014-06-18 洛阳惠中兽药有限公司 Traditional Chinese medicinal composition, and preparation method and application thereof
CN103720769A (en) * 2013-12-16 2014-04-16 扬子江药业集团广州海瑞药业有限公司 Traditional Chinese medicinal composition capable of enhancing immunity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1135904A (en) * 1995-05-16 1996-11-20 唐延军 Oral liquid of shengxueyin
CN1205880A (en) * 1996-01-23 1999-01-27 陈明 Immune anticancer medicine
CN1217929A (en) * 1997-11-20 1999-06-02 张志刚 Chinese medicine for AlDs and preparing process therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1135904A (en) * 1995-05-16 1996-11-20 唐延军 Oral liquid of shengxueyin
CN1205880A (en) * 1996-01-23 1999-01-27 陈明 Immune anticancer medicine
CN1217929A (en) * 1997-11-20 1999-06-02 张志刚 Chinese medicine for AlDs and preparing process therefor

Also Published As

Publication number Publication date
CN1943661A (en) 2007-04-11

Similar Documents

Publication Publication Date Title
CN101716280B (en) Medicine composite used for curing liver cancer
CN102940779A (en) Medicine composition for treating chronic ulcerative colitis and preparation process of medicine composition
CN102302608B (en) Chinese medicinal composition for treating anemia and preparation method thereof
CN102058805A (en) Oral medicine for preventing and treating leukocytopenia caused by chemotherapy
CN103251856B (en) Traditional Chinese medicine preparation for benefiting Qi and nourishing blood and preparation method of traditional Chinese medicine preparation
CN102657736B (en) Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition
CN1943661B (en) A Chinese traditional medicinal composition and its preparation method
CN104042895A (en) Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof
CN102335249B (en) Oral capsule for treating II-type diabetes
CN1931336B (en) Chinese medicine composition and its preparation process
CN105853618A (en) Traditional Chinese medicine composition with broad-spectrum anti-cancer effect as well as preparation method and application thereof
CN102652774A (en) Drug composition for treating leukopenia and hypoimmunity caused by chemoradiotherapy and preparation method and quality detection method
CN105362904A (en) Qi tonifying and blood nourishing traditional Chinese medicinal pill and preparation method thereof
CN101675961B (en) A medicinal preparation for treating breast cancer and preparation method thereof
CN102205031B (en) Traditional Chinese medicine for treating male sterility
CN101543597A (en) Medicine composition for nourishing spleen and kidney and building up healthful vital energy and preparation method thereof
CN1943677A (en) A Chinese traditional medicinal composition and its preparation method
CN100471488C (en) Chinese medicine composition for transquilizing, warming Yang, benefiting Qi and nourishing heart and its prepn
CN103566349A (en) Medicinal composition for treating hyperglycemia and hyperlipidemia
CN103191293A (en) Sub-health-preventive drug composition and preparation method thereof
CN102836315A (en) Chinese medicinal composition for preventing and conditioning prognosis tumors and preparation method thereof
CN103006891A (en) Medicine composition for treating chronic renal failure
CN102258626A (en) Traditional Chinese medicine compound Tenghuanglin, preparation method and application thereof
CN1330338C (en) Medicine for reinforcing primordial qi of late stage cancer patents
CN1931352A (en) Chinese medicine composition and its prepn process

Legal Events

Date Code Title Description
PB01 Publication
C06 Publication
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 100012 DONGCHENG, BEIJING TO: 225300 TAIZHOU, JIANGSU PROVINCE

C41 Transfer of patent application or patent right or utility model
ASS Succession or assignment of patent right

Owner name: SHI MENG

Free format text: FORMER OWNER: ZHOU XIAOMING

Effective date: 20150106

TR01 Transfer of patent right

Effective date of registration: 20150106

Address after: 225300 Jiangsu province Taizhou city Gaogang District Jinhua Dragon Court building 22 room 1102

Patentee after: Shi Meng

Address before: 100012, No. 10, Qinglong dragon alley, Dongcheng District, Beijing

Patentee before: Zhou Xiaoming

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: ZHOU XIAOMING TO: SHI MENG

Free format text: CORRECT: ADDRESS; FROM: 225300 TAIZHOU, JIANGSU PROVINCE TO: 510663 GUANGZHOU, GUANGDONG PROVINCE

C53 Correction of patent for invention or patent application
CB03 Change of inventor or designer information

Inventor after: Shi Meng

Inventor before: Zhou Xiaoming

TR01 Transfer of patent right

Effective date of registration: 20150121

Address after: 510663 No. 31 Xiangshan Road, Science City, Guangdong, Guangzhou

Patentee after: Yangzijiang Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co.,Ltd.

Address before: 225300 Jiangsu province Taizhou city Gaogang District Jinhua Dragon Court building 22 room 1102

Patentee before: Shi Meng

C41 Transfer of patent application or patent right or utility model
ASS Succession or assignment of patent right

Owner name: YANGTZE RIVER PHARMACEUTICAL GROUP GUANGZHOU HAIRU

Free format text: FORMER OWNER: SHI MENG

Effective date: 20150121